MedPath

Atreca, Inc.

Atreca, Inc. logo
🇺🇸United States
Ownership
Private
Established
2010-01-01
Employees
90
Market Cap
-
Website
http://www.atreca.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Phase 1
Terminated
Conditions
Breast Cancer
Colorectal Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Acral Lentiginous Melanoma
Head and Neck Squamous Cell Carcinoma
Hepatocellular Carcinoma
Esophageal Squamous Cell Carcinoma
Urothelial Carcinoma
DMMR Colorectal Cancer
Interventions
Biological: ATRC-101
Biological: Pembrolizumab
First Posted Date
2020-01-28
Last Posted Date
2023-12-29
Lead Sponsor
Atreca, Inc.
Target Recruit Count
87
Registration Number
NCT04244552
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

The University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 14 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.